

LIGAND PHARMACEUTICALS INC  
Form 4  
November 13, 2015

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL  
OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Herman Melanie J

2. Issuer Name and Ticker or Trading Symbol  
LIGAND PHARMACEUTICALS INC [LGND]

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Director of Accounting

(Last) (First) (Middle)  
11119 NORTH TORREY PINES ROAD, SUITE 200  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
11/11/2015

LA JOLLA, CA 92037

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	11/11/2015		M	469 A	\$ 11.15	3,620	D
Common Stock	11/11/2015		M	625 A	\$ 11.91	4,245	D
Common Stock	11/11/2015		M	1,500 A	\$ 14.47	5,745	D
Common Stock	11/11/2015		M	312 A	\$ 21.92	6,057	D
Common Stock	11/11/2015		M	2,500 A	\$ 74.42	8,557	D

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

Common Stock	11/11/2015	M	625	A	\$ 68.48	9,182	D
Common Stock	11/11/2015	M	1,688	A	\$ 56.26	10,870	D
Common Stock	11/11/2015	S	7,719	D	\$ 101	3,151	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 11.15	11/11/2015	11/11/2015	M	469	<u>(1)</u> 05/02/2021	Common Stock	469	
Employee Stock Option (right to buy)	\$ 11.91	11/11/2015	11/11/2015	M	625	<u>(2)</u> 01/03/2022	Common Stock	625	
Employee Stock Option (right to buy)	\$ 14.47	11/11/2015	11/11/2015	M	1,500	<u>(3)</u> 02/09/2022	Common Stock	1,500	
Employee Stock Option (right to buy)	\$ 21.92	11/11/2015	11/11/2015	M	312	<u>(4)</u> 02/15/2023	Common Stock	312	



## Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/12/14.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.